Literature DB >> 7965527

Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome.

M P La Quaglia1, B H Kushner, G Heller, M A Bonilla, K L Lindsley, N K Cheung.   

Abstract

The importance of gross total resection of the primary tumor in stage 4 neuroblastoma is controversial. The purpose of this study was to assess the impact of gross total resection of the primary tumor on clinical outcome in patients with stage 4 neuroblastoma diagnosed at more than 1 year of age. The authors retrospectively analyzed 70 newly diagnosed cases treated with one of five regimens of increasing dose-intensity. Outcome variables included survival time from diagnosis, and time to local recurrence or local tumor progression. Patient variables analyzed for impact on survival included age, anatomic location of the primary tumor, radiation treatment of the primary site, complete resection at diagnosis, gross total resection (GTR) at any time in the course of therapy, and treatment protocol dose-intensity. GTR was accomplished in seven patients at the time of diagnosis and in 32 patients after chemotherapy. The likelihood of complete gross resection after chemotherapy increased with greater protocol intensity. The only patient variables that correlated with improved survival were GTR (P = .03) and chemotherapy protocol (P = .01). GTR was also associated with improved local control. Although an independent effect of GTR on survival was not demonstrable because complete resection after chemotherapy correlated strongly with increasing protocol intensity, its association with improved overall survival was striking. These results support a continued role for GTR in high-risk neuroblastoma, along with intensive chemotherapy.

Entities:  

Mesh:

Year:  1994        PMID: 7965527     DOI: 10.1016/0022-3468(94)90301-8

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  19 in total

1.  Kinetics of primary tumor regression with chemotherapy: implications for the timing of surgery.

Authors:  I Medary; D Aronson; N K Cheung; F Ghavimi; W Gerald; M P La Quaglia
Journal:  Ann Surg Oncol       Date:  1996-11       Impact factor: 5.344

Review 2.  Neuroblastoma.

Authors:  S Shah; Y Ravindranath
Journal:  Indian J Pediatr       Date:  1998 Sep-Oct       Impact factor: 1.967

Review 3.  Cellular kinetics of neuroblastoma and the role of surgery.

Authors:  Tatsuo Kuroda
Journal:  Pediatr Surg Int       Date:  2011-07-19       Impact factor: 1.827

Review 4.  The role of surgery in the treatment of neuroblastoma.

Authors:  Masayuki Kubota
Journal:  Surg Today       Date:  2010-05-23       Impact factor: 2.549

5.  Implications of surgical intervention in the treatment of neuroblastomas: 20-year experience of a single institution.

Authors:  Tatsuro Tajiri; Ryota Souzaki; Yoshiaki Kinoshita; Yuhki Koga; Aiko Suminoe; Toshiro Hara; Tomoaki Taguchi
Journal:  Surg Today       Date:  2012-01-19       Impact factor: 2.549

6.  The role of complete surgical resection in stage IV neuroblastoma.

Authors:  Patrick J Bastian; Gudrun Fleischhack; Martina Zimmermann; Carola Hasan; Udo Bode; Stefan C Müller; Stefan Schumacher
Journal:  World J Urol       Date:  2004-09-14       Impact factor: 4.226

7.  Intraoperative radiation therapy for advanced neuroblastoma: the problem of securing the IORT field.

Authors:  Kiminobu Sugito; Takeshi Kusafuka; Mayumi Hoshino; Mikiya Inoue; Hiroshi Goto; Taro Ikeda; Noritsugu Hagiwara; Tsugumichi Koshinaga; Masahiro Fukuzawa; Masanori Nakamura; Hiroyuki Shichino; Motoaki Chin; Hideo Mugishima; Tsutomu Saito; Yoshiaki Tanaka
Journal:  Pediatr Surg Int       Date:  2007-10-30       Impact factor: 1.827

8.  Locoregional tumor progression after radiation therapy influences overall survival in pediatric patients with neuroblastoma.

Authors:  Atmaram S Pai Panandiker; Lisa McGregor; Matthew J Krasin; Shengjie Wu; Xiaoping Xiong; Thomas E Merchant
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-08-11       Impact factor: 7.038

Review 9.  Neuroblastoma: evolving therapies for a disease with many faces.

Authors:  Robert E Goldsby; Katherine K Matthay
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

10.  Combined application of Indocyanine green (ICG) and laser lead to targeted tumor cell destruction.

Authors:  Jordan S Taylor; Jasmine Zeki; Naohiko Ikegaki; Liaohai L Chen; Bill Chiu
Journal:  J Pediatr Surg       Date:  2018-09-04       Impact factor: 2.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.